Relmada Therapeutics, Inc.
NASDAQ:RLMDBiotechnology
-$0.06 today
- Market cap
- $304.61M
- Beta
- 0.39
- P/E (TTM)
- -9.6
- EPS (TTM)
- -$0.68
Volume 1.86M
Average 1.24M
RLMD Total Current Liabilities
All obligations due within one year.
Relmada Therapeutics, Inc.NASDAQ: RLMD
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities rises 146.4% from a year ago
Total current liabilities stood at $12.89M at the end of Q1 FY2026, up 146.4% from a year earlier and up 100.5% from the prior quarter. Over 3 fiscal years it compounded at -19.8% a year.
Context
- Total current liabilities amounted to 5.5% of total assets at the end of Q1 FY2026, down 13.4 pp from a year earlier.
- Total current liabilities increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +146.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 6.43M USD
- Year-over-year change
- -37.5%
- 4-year CAGR
- -19.2%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.43M | -37.5% |
| FY2024 | 2024-12-31 | 10.29M | -15.6% |
| FY2023 | 2023-12-31 | 12.19M | -2.2% |
| FY2022 | 2022-12-31 | 12.47M | -17.2% |
| FY2021 | 2021-12-31 | 15.06M | — |
Total Current Liabilities vs competitors
How RLMD compares with its peers on the latest reported figures
- RLMD's Mar 2026 total current liabilities of $12.89M is the 7th highest of the 9 companies compared; the peer median is $19.13M.
- Its year-over-year change of +146.4% is the highest of 9, against a peer median of -15.2%.
- Total current liabilities amounts to 5.5% of total assets for RLMD, versus a peer median of 10.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $103.39M | +40.3% | -27.0% | 29.0% | |
| Mar 2026 | $76.84M | -22.0% | +69.2% | 42.7% | |
| Mar 2026 | $38.36M | +49.9% | +32.8% | 20.2% | |
| Mar 2026 | $19.97M | -33.0% | +2.6% | 9.9% | |
| Mar 2026 | $18.3M | +11.3% | +3.0% | 10.8% | |
CBUSCibus, Inc. | Mar 2026 | $13.94M | -33.6% | +116.5% | 4.3% |
| Mar 2026 | $12.89M | +146.4% | -19.8% | 5.5% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | Mar 2026 | $11.05M | -18.4% | +34.0% | 10.3% |
| Mar 2026 | $8.6M | -11.9% | +1.8% | 8.9% | |
| Peer median (excluding RLMD) | $19.13M | -15.2% | +17.9% | 10.5% | |
Competitors are the stored peer set for RLMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 44.44M | 5.4M | 4.09M | 3.86M | 3.5M |
| Short-term Investments | 167.47M | 142.93M | 92.23M | 41.05M | 89.51M |
| Net Receivables | 86.38K | 512.43K | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 35 | 0 | 0 | 0 | 0 |
| Total Current Assets | 223.3M | 152.87M | 97.51M | 45.8M | 93.98M |
| Property, Plant & Equipment (Net) | 0 | 0 | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 28.29K | 34.88K | 43.13K | 21.98K | 19.5K |
| Total Non-current Assets | 28.29K | 34.88K | 43.13K | 21.98K | 19.5K |
| Total Assets | 223.33M | 152.91M | 97.55M | 45.82M | 94M |
| Account Payables | 11.19M | 5.26M | 3.51M | 4.13M | 1.57M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.64M | 1.02M | 5.68M | 1.15M | 535.48K |
| Total Current Liabilities | 15.06M | 12.47M | 12.19M | 10.29M | 6.43M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 4.47K | 1.06M |
| Total Non-current Liabilities | 0 | 0 | 0 | 4.47K | 1.06M |
| Total Liabilities | 15.06M | 12.47M | 12.19M | 10.3M | 7.49M |
| Common Stock | 27.74K | 30.1K | 30.1K | 30.17K | 73.33K |
| Retained Earnings | (305.07M) | (462.11M) | (560.9M) | (640.88M) | (698.27M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 208.26M | 140.44M | 85.36M | 35.52M | 86.51M |
| Total Debt | 0 | 0 | 0 | 0 | 0 |
| Net Debt | (44.44M) | (5.4M) | (4.09M) | (3.86M) | (3.5M) |
Relmada Therapeutics, Inc.
NASDAQ:RLMD
Intrinsic Alpha fair value
Locked
Current Price
$2.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.